In vivo effects of a novel inhibitor of apoptosis signal-regulating kinase 1 (ASK1) in mouse models of liver injury and metabolic disease

Manuel Roqueta-Rivera, Mary D. Chau, Guoqiang Wang, Jun Ma, Kelsey Garlick, Bindu Ramachandran, Susanne Fyfe, Khanh Hoang, Lijuan Jiang, Yat Sun Or, and Bryan Goodwin Enanta Pharmaceuticals, Inc., Watertown, MA, USA

BACKGROUND AND AIM

Apoptosis Signal-Regulating Kinase 1 (ASK1) is a redox-sensitive kinase. In the setting of oxidative stress, ASK1 activates mitogenactivated protein kinase (MAPK) signalling which, in turn, modulates the activity of apoptotic and inflammatory pathways. As a result, inhibition of ASK1 has been proposed as a therapeutic approach for the treatment of non-alcoholic steatohepatitis (NASH). EP-027315 is a novel, highly selective, and potent (IC₅₀ < 1.25 nM) ASK1 inhibitor. Here, we evaluate the *in vivo* efficacy of EP-027315 in mouse models of liver injury (acetaminophen toxicity) and metabolic disease (diet-induced obesity).






Figure1. ASK1 activation in response to excess reactive oxygen species (ROS) due to glutathione (GSH) depletion in liver injury model of acetaminophen (APAP), or due to excess fatty acids in dietinduced obesity (DIO), leads to apoptosis and inflammation.

METHODS

In Vitro. Biochemical IC₅₀ of ASK1 inhibitors (ASK1i) was determined by TR-FRET (Cisbio KinEASE-STK S3 kit). Cell-based IC₅₀ was evaluated in hydrogen peroxide (H_2O_2) -treated HEK293 cells stably expressing human ASK1, pre-incubated with ASK1i. Binding affinity (KdElect) and kinase selectivity (ScanMax) assays were performed by DiscoverX.

In Vivo. Inhibition of ASK1 activation was tested in C57BL/6 male mice (8 weeks of age) receiving a single dose of vehicle or EP-027315 (oral gavage) 1 hour prior to acetaminophen (APAP) administration (300 mg/kg, i.p). Livers and plasma were harvested 6 hours after APAP treatment to evaluate the effects of EP-027315 on hepatic ASK1 signalling. To further characterize the pharmacologic effects of ASK1 inhibition on APAP-mediated hepatotoxicity, RNA-Seq analysis of livers was performed. In addition, inhibition of ASK1 was evaluated in diet-induced obese (DIO) mice fed a high-fat diet (D12492) for 24 weeks and dosed with ASK1i for 2 consecutive days. Three hours after the last dose, liver was harvested for protein and RNA analysis. In both models, MAPK signalling and apoptotic markers were evaluated using immunoblot or MSD (Mesoscale Discovery) assay. Hepatic injury and inflammation were assessed by plasma ALT, plasma IL-1 β , and histological evaluation of formalin-fixed tissues.







Pharmaceuticals

FRI-340





© Enanta Pharmaceuticals, Inc.